Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Elite suppressors have low frequencies of intact HIV-1 proviral DNA.

Kr Kwaa A, Garliss CC, Ritter KD, Laird GM, Blankson JN.

AIDS. 2019 Dec 27. doi: 10.1097/QAD.0000000000002474. [Epub ahead of print]

PMID:
31895150
2.

Subclinical cardiovascular disease in HIV controller and long-term nonprogressor populations.

Brusca RM, Hanna DB, Wada NI, Blankson JN, Witt MD, Jacobson LP, Kingsley L, Palella FJ Jr, Budoff M, Brown TT, Anastos K, Lazar JM, Mack WJ, Bacchetti P, Tien PC, Golzar Y, Plankey M, Golub E, Kaplan RC, Post WS.

HIV Med. 2019 Nov 14. doi: 10.1111/hiv.12820. [Epub ahead of print]

PMID:
31729142
3.

Challenges in optimizing preexposure prophylaxis development, engagement, and access for HIV prevention.

Scully EP, Weld ED, Blankson JN.

J Clin Invest. 2019 Dec 2;129(12):5071-5073. doi: 10.1172/JCI134389. No abstract available.

4.

Does B Cell Follicle Exclusion of CD8+ T Cells Make Lymph Nodes Sanctuaries of HIV Replication?

Beck SE, Veenhuis RT, Blankson JN.

Front Immunol. 2019 Oct 9;10:2362. doi: 10.3389/fimmu.2019.02362. eCollection 2019. Review.

5.

A quantitative approach for measuring the reservoir of latent HIV-1 proviruses.

Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, Fray EJ, Beg SA, Antar AAR, Jenike KM, Bertagnolli LN, Capoferri AA, Kufera JT, Timmons A, Nobles C, Gregg J, Wada N, Ho YC, Zhang H, Margolick JB, Blankson JN, Deeks SG, Bushman FD, Siliciano JD, Laird GM, Siliciano RF.

Nature. 2019 Feb;566(7742):120-125. doi: 10.1038/s41586-019-0898-8. Epub 2019 Jan 30.

6.

Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Kwaa AKR, Talana CAG, Blankson JN.

J Virol. 2019 Jan 17;93(3). pii: e01541-18. doi: 10.1128/JVI.01541-18. Print 2019 Feb 1.

7.

Long-term remission despite clonal expansion of replication-competent HIV-1 isolates.

Veenhuis RT, Kwaa AK, Garliss CC, Latanich R, Salgado M, Pohlmeyer CW, Nobles CL, Gregg J, Scully EP, Bailey JR, Bushman FD, Blankson JN.

JCI Insight. 2018 Sep 20;3(18). pii: 122795. doi: 10.1172/jci.insight.122795. eCollection 2018 Sep 20.

8.

CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans.

El-Diwany R, Soliman M, Sugawara S, Breitwieser F, Skaist A, Coggiano C, Sangal N, Chattergoon M, Bailey JR, Siliciano RF, Blankson JN, Ray SC, Wheelan SJ, Thomas DL, Balagopal A.

Sci Adv. 2018 Aug 1;4(8):eaat0843. doi: 10.1126/sciadv.aat0843. eCollection 2018 Aug.

9.

Highly Attenuated Infection With a Vpr-Deleted Molecular Clone of Human Immunodeficiency Virus-1.

Ali A, Ng HL, Blankson JN, Burton DR, Buckheit RW 3rd, Moldt B, Fulcher JA, Ibarrondo FJ, Anton PA, Yang OO.

J Infect Dis. 2018 Sep 22;218(9):1447-1452. doi: 10.1093/infdis/jiy346.

10.

Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses.

Pohlmeyer CW, Laskey SB, Beck SE, Xu DC, Capoferri AA, Garliss CC, May ME, Livingston A, Lichmira W, Moore RD, Leffell MS, Butler NJ, Thorne JE, Flynn JA, Siliciano RF, Blankson JN.

PLoS One. 2018 Feb 21;13(2):e0192098. doi: 10.1371/journal.pone.0192098. eCollection 2018.

11.

The mouse viral outgrowth assay: avatars for the detection of HIV-1 reservoirs.

Metcalf Pate KA, Blankson JN.

Retrovirology. 2017 Nov 21;14(1):52. doi: 10.1186/s12977-017-0376-z. Review.

12.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

13.

HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.

Veenhuis RT, Freeman ZT, Korleski J, Cohen LK, Massaccesi G, Tomasi A, Boesch AW, Ackerman ME, Margolick JB, Blankson JN, Chattergoon MA, Cox AL.

J Clin Invest. 2017 Dec 1;127(12):4352-4364. doi: 10.1172/JCI95375. Epub 2017 Oct 30.

14.

The Antiviral Immune Response and Its Impact on the HIV-1 Reservoir.

Veenhuis RT, Blankson JN.

Curr Top Microbiol Immunol. 2018;417:43-67. doi: 10.1007/82_2017_72. Review.

PMID:
29071476
15.

HIV-1 reservoirs in elite controllers: clues for developing a functional cure?

May ME, Kwaa AK, Blankson JN.

Future Microbiol. 2017 Sep;12:1019-1022. doi: 10.2217/fmb-2017-0163. Epub 2017 Aug 24. No abstract available.

16.

Characterization of Elite Suppressors Cell-Associated HIV-1 mRNA at Baseline and with T Cell Activation

.

Pohlmyer CW, Bullen CK, Martin AR, Laird GM, Chioma SU, Walker-Sperling VEK, Blankson JN.

Yale J Biol Med. 2017 Jun 23;90(2):331-336. eCollection 2017 Jun.

17.

Weak HIV Antibody Responses in Perinatally Infected Young Adults: Weak HIV Antibody Responses in Perinatally Infected Adults.

Kirkpatrick AR, Unsal AB, Blankson JN, Moore RD, Quinn TC, Hadigan C, Laeyendecker O.

Pediatr Infect Dis J. 2017 Nov;36(11):1064-1066. doi: 10.1097/INF.0000000000001649.

18.

The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells.

Kwaa AK, Goldsborough K, Walker-Sperling VE, Pianowski LF, Gama L, Blankson JN.

PLoS One. 2017 May 3;12(5):e0174516. doi: 10.1371/journal.pone.0174516. eCollection 2017.

19.

A CD3/CD28 microbead-based HIV-1 viral outgrowth assay.

Kuzmichev YV, Veenhuis RT, Pohlmeyer CW, Garliss CC, Walker-Sperling VE, Blankson JN.

J Virus Erad. 2017 Apr 1;3(2):85-89.

20.

Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals.

El-Diwany R, Breitwieser FP, Soliman M, Skaist AM, Srikrishna G, Blankson JN, Ray SC, Wheelan SJ, Thomas DL, Balagopal A.

AIDS. 2017 Jun 19;31(10):1405-1414. doi: 10.1097/QAD.0000000000001480.

21.

Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller.

Walker-Sperling VE, Pohlmeyer CW, Veenhuis RT, May M, Luna KA, Kirkpatrick AR, Laeyendecker O, Cox AL, Carrington M, Bailey JR, Arduino RC, Blankson JN.

EBioMedicine. 2017 Feb;16:141-149. doi: 10.1016/j.ebiom.2017.01.034. Epub 2017 Jan 26.

22.

Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection.

Wendel SK, Longosz AF, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Quinn TC, Laeyendecker O.

AIDS Res Hum Retroviruses. 2017 Apr;33(4):325-327. doi: 10.1089/AID.2016.0105. Epub 2017 Jan 11.

23.

The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.

Walker-Sperling VE, Pohlmeyer CW, Tarwater PM, Blankson JN.

EBioMedicine. 2016 Jun;8:217-229. doi: 10.1016/j.ebiom.2016.04.019. Epub 2016 Apr 18.

24.

What can we do to reduce the viral reservoir in HIV-1-infected individuals?

Pohlmeyer CW, Walker-Sperling VE, Blankson JN.

Future Microbiol. 2016 Jul;11:839-42. doi: 10.2217/fmb-2016-0074. Epub 2016 Jul 15. No abstract available.

25.

Short Communication: HIV Controller T Cells Effectively Inhibit Viral Replication in Alveolar Macrophages.

Walker-Sperling VE, Merlo CA, Buckheit RW 3rd, Lambert A, Tarwater P, Kirk GD, Drummond MB, Blankson JN.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):1097-1099. Epub 2016 Aug 2.

26.

Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.

Kirkpatrick AR, Patel EU, Celum CL, Moore RD, Blankson JN, Mehta SH, Kirk GD, Margolick JB, Quinn TC, Eshleman SH, Laeyendecker O.

AIDS Res Hum Retroviruses. 2016 Aug;32(8):756-62. doi: 10.1089/AID.2015.0198. Epub 2016 May 5.

27.

Immune Control Despite Protracted Lymphopenia After Chemoradiation in an Elite Controller.

Reiss KA, Jackson DC, Piotrowski A, Grossman S, Blankson JN.

Open Forum Infect Dis. 2016 Jan 29;3(1):ofw016. doi: 10.1093/ofid/ofw016. eCollection 2016 Jan.

28.

Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.

Akkina R, Allam A, Balazs AB, Blankson JN, Burnett JC, Casares S, Garcia JV, Hasenkrug KJ, Kashanchi F, Kitchen SG, Klein F, Kumar P, Luster AD, Poluektova LY, Rao M, Sanders-Beer BE, Shultz LD, Zack JA.

AIDS Res Hum Retroviruses. 2016 Feb;32(2):109-19. doi: 10.1089/AID.2015.0258.

29.

A Human Immunodeficiency Virus Controller With a Large Population of CD4(+)CD8(+) Double-Positive T Cells.

Durand CM, Buckheit RW 3rd, Salgado M, Pohlmeyer CW, Walker-Sperling VE, Hegarty RW, Ambinder RF, Blankson JN.

Open Forum Infect Dis. 2015 Mar 20;2(2):ofv039. doi: 10.1093/ofid/ofv039. eCollection 2015 Apr.

30.

Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.

Walker-Sperling VE, Cohen VJ, Tarwater PM, Blankson JN.

J Virol. 2015 Sep;89(18):9631-8. doi: 10.1128/JVI.01454-15. Epub 2015 Jul 15.

31.

Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro.

Sampah ME, Laird GM, Blankson JN, Siliciano RF, Coleman JS.

AIDS. 2015 Jun 19;29(10):1137-46. doi: 10.1097/QAD.0000000000000681.

32.

A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads.

Metcalf Pate KA, Pohlmeyer CW, Walker-Sperling VE, Foote JB, Najarro KM, Cryer CG, Salgado M, Gama L, Engle EL, Shirk EN, Queen SE, Chioma S, Vermillion MS, Bullock B, Li M, Lyons CE, Adams RJ, Zink MC, Clements JE, Mankowski JL, Blankson JN.

J Infect Dis. 2015 Nov 1;212(9):1387-96. doi: 10.1093/infdis/jiv230. Epub 2015 Apr 15.

33.

Candida esophagitis in a human immunodeficiency virus-1-positive elite controller with hepatitis C virus cirrhosis.

Chen A, Shieh E, Brinkley S, Blankson JN.

Open Forum Infect Dis. 2014 Dec 23;1(3):ofu111. doi: 10.1093/ofid/ofu111. eCollection 2014 Dec.

34.

Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.

Crowell TA, Gebo KA, Blankson JN, Korthuis PT, Yehia BR, Rutstein RM, Moore RD, Sharp V, Nijhawan AE, Mathews WC, Hanau LH, Corales RB, Beil R, Somboonwit C, Edelstein H, Allen SL, Berry SA; HIV Research Network.

J Infect Dis. 2015 Jun 1;211(11):1692-702. doi: 10.1093/infdis/jiu809. Epub 2014 Dec 15.

35.

Finding a cure for human immunodeficiency virus-1 infection.

Blankson JN, Siliciano JD, Siliciano RF.

Infect Dis Clin North Am. 2014 Dec;28(4):633-50. doi: 10.1016/j.idc.2014.08.007. Epub 2014 Sep 30. Review.

36.

Comparative analysis of the capacity of elite suppressor CD4+ and CD8+ T cells to inhibit HIV-1 replication in monocyte-derived macrophages.

Walker-Sperling VE, Buckheit RW 3rd, Blankson JN.

J Virol. 2014 Sep 1;88(17):9789-98. doi: 10.1128/JVI.00860-14. Epub 2014 Jun 18.

37.

Long-term control of viral replication in a Group O, human immunodeficiency virus type 1-infected individual.

Buckheit RW 3rd, Sexauer SB, Sedaghat AR, Wilke CO, Laeyendecker O, Basseth CR, Blankson JN.

AIDS Res Hum Retroviruses. 2014 Jun;30(6):511-3. doi: 10.1089/AID.2014.0054. No abstract available.

38.

HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon.

Chattergoon MA, Latanich R, Quinn J, Winter ME, Buckheit RW 3rd, Blankson JN, Pardoll D, Cox AL.

PLoS Pathog. 2014 May 1;10(5):e1004082. doi: 10.1371/journal.ppat.1004082. eCollection 2014 May.

39.

Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening.

Piwowar-Manning E, Fogel JM, Laeyendecker O, Wolf S, Cummings V, Marzinke MA, Clarke W, Breaud A, Wendel S, Wang L, Swanson P, Hackett J Jr, Mannheimer S, Del Rio C, Kuo I, Harawa NT, Koblin BA, Moore R, Blankson JN, Eshleman SH.

HIV Clin Trials. 2014 Mar-Apr;15(2):62-8. doi: 10.1310/hct1502-62.

40.

HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice.

Salgado M, Swanson MD, Pohlmeyer CW, Buckheit RW 3rd, Wu J, Archin NM, Williams TM, Margolis DM, Siliciano RF, Garcia JV, Blankson JN.

J Virol. 2014 Mar;88(6):3340-52. doi: 10.1128/JVI.03380-13. Epub 2014 Jan 3.

41.

CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants.

Pohlmeyer CW, Buckheit RW 3rd, Siliciano RF, Blankson JN.

Retrovirology. 2013 Dec 12;10:152. doi: 10.1186/1742-4690-10-152.

42.

Sprouty-2 regulates HIV-specific T cell polyfunctionality.

Chiu YL, Shan L, Huang H, Haupt C, Bessell C, Canaday DH, Zhang H, Ho YC, Powell JD, Oelke M, Margolick JB, Blankson JN, Griffin DE, Schneck JP.

J Clin Invest. 2014 Jan;124(1):198-208.

43.

Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.

Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF.

Cell. 2013 Oct 24;155(3):540-51. doi: 10.1016/j.cell.2013.09.020. Epub 2013 Oct 24.

44.

Evolution of an attenuated HIV-1 isolate in an elite suppressor.

Salgado M, Gandhi S, Buckheit RW, Berkenblit GV, Blankson JN.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):284-8. doi: 10.1089/AID.2013.0229. Epub 2013 Nov 13.

45.

Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells.

Buckheit RW 3rd, Siliciano RF, Blankson JN.

Retrovirology. 2013 Jul 1;10:68. doi: 10.1186/1742-4690-10-68.

46.

Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay.

Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, Siliciano JD, Siliciano RF.

PLoS Pathog. 2013;9(5):e1003398. doi: 10.1371/journal.ppat.1003398. Epub 2013 May 30.

47.

Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.

Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Brookmeyer R, Quinn TC, Laeyendecker O.

PLoS One. 2013;8(2):e55525. doi: 10.1371/journal.pone.0055525. Epub 2013 Feb 20.

48.

Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors.

Buckheit RW 3rd, Salgado M, Silciano RF, Blankson JN.

J Virol. 2012 Dec;86(24):13679-88. doi: 10.1128/JVI.02439-12. Epub 2012 Oct 10.

49.

Developing strategies for HIV-1 eradication.

Durand CM, Blankson JN, Siliciano RF.

Trends Immunol. 2012 Nov;33(11):554-62. doi: 10.1016/j.it.2012.07.001. Epub 2012 Aug 3. Review.

50.

The implications of viral reservoirs on the elite control of HIV-1 infection.

Buckheit RW 3rd, Salgado M, Martins KO, Blankson JN.

Cell Mol Life Sci. 2013 Mar;70(6):1009-19. doi: 10.1007/s00018-012-1101-7. Epub 2012 Aug 4. Review.

PMID:
22864624

Supplemental Content

Loading ...
Support Center